menu

CME: Real-World Treatment Effectiveness Compared with Clinical Trial Efficacy in Multiple Myeloma: A Focus on the EU

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Real-World Treatment Effectiveness Compared with Clinical Trial Efficacy in Multiple Myeloma: A Focus on the EU

Program Information
Recommended
Real-World Treatment Effectiveness Compared with Clinical Trial Efficacy in Multiple Myeloma: A Focus on the EU
RestartResume
New agents and regimens for multiple myeloma have seen great success in clinical trials, but how are these treatment options faring in the real world?

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Substantial improvements in survival have been seen in patients with multiple myeloma (MM) thanks to the introduction of multiple novel agents and regimens. However, these therapies and approaches may have limitations due to the differences in well-controlled, patient-restricted clinical trials and real-world settings.  And since this discrepancy has already been seen firsthand in the EU, it’s essential that clinicians fully anticipate the real-world effectiveness of approved treatments for MM so they can optimize outcomes for their patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kenneth C. Anderson, MD
    Medical Oncologist
    Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, MA

    Dr. Anderson is on the advisory board at Celgene, Bristol Myers Squibb, Takeda, Janssen, Gilead, Sanofi, Precision Bioscience.  He has ownership interest in Oncopep and C4 Therapeutics.

    Faculty: 
    Philippe Moreau, MD
    Hematology Department
    University Hospital Hôtel-Dieu
    France

    Dr. Moreau receives consulting fees from Amgen, Celgene, Janssen, and Takeda.

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian McDonough, MD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Lawrence Sherman, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the differences between real-world effectiveness and clinical trial efficacy of therapeutic options in multiple myeloma
    • Outline appropriate treatment regimens in multiple myeloma based on all available evidence
  • Target Audience

    This activity is designed to meet the educational needs of hematologist/oncologists and other members of the interprofessional team who are involved in the management of patients with multiple myeloma.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.  

  • Commercial Support

    This activity is supported by an independent educational grant from Takeda Oncology.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/15/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.